BIIB just had their AD drug rejected by the FDA, AVXL dropped 30% after yet another disappointing presentation that didn't include any mentions of placebo controls or meaningful improvement in patients, and NTRP will split in half and run out of money before the next trial is finished unless they raise more money and dilute existing shareholders.
Better to stay far away from this space for the next year or two while there's nothing meaningful on the horizon in the short-term.